Providing More Patients Greater Access to Lifesaving Medicines
Biologics are innovative treatment options for patients affected by debilitating and life-threatening diseases. However, they are often associated with high costs and limited patient access. Biosimilar medicines are a solution that provide greater access to these advanced therapies for patients. As biosimilars become more widely available in the United States, they expand therapeutic options, enhancing the likelihood that patients will be able to begin treatment with biologic medicines. An analysis by Avalere Health for the Biosimilars Council shows that 1.2 million U.S. patients could gain access to biologics by 2025 as the result of biosimilar availability.
This data also suggests that women, lower income, and elderly individuals would disproportionately benefit from access to biosimilar medicines.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at www.accesiblemeds.org.
